Compare Amgen, Inc. (AMGN) vs General Mills, Inc. (GIS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs General Mills, Inc. — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while General Mills, Inc. trades at $36.31 (market cap $19.33B). The key difference: Amgen, Inc. is far larger — about 10.1× General Mills, Inc.'s market cap, and General Mills, Inc. pays the higher dividend (6.74%). Which is the better fit depends on your goals.
| AMGN | GIS | |
|---|---|---|
Market Cap | $196.12B | $19.33B |
Sector | Health | Consumer Staples |
52-Week High | $388.16 | $51.60 |
52-Week Low | $271.18 | $32.17 |
Enterprise Value | $241.41B | $32.82B |
Dividend Yield | 2.77% | 6.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
General Mills (GIS) trades at $36.22, up 1.03% on the day, near the analyst consensus price target of $36.14. The stock presents a mixed picture with a low P/E of 9.23 suggesting value, but profitability metrics like a negative net income margin and ROE for 2026 signal challenges. Recent Q2 2026 earnings beat expectations, yet the technical outlook is bearish, and news highlights sales pressure and a focus on cost savings to drive a margin recovery in fiscal 2027.
The investment outlook is cautious. The stock's low valuation and dividend yield offer potential value, but persistent sales softness, margin pressure from competition, and a high debt-to-asset ratio of 45% pose significant risks. Analyst sentiment is predominantly neutral to negative, with a majority hold rating, indicating a wait-and-see approach is warranted until clearer signs of sustainable growth emerge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →
